UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1325-6
Program Prior Authorization-Notification
Medication Reyvow® (lasmiditan)
P&T Approval Date 8/2020, 7/2021, 3/2022, 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Reyvow (lasmiditan) is a serotonin 5-HT receptor agonist indicated for the acute treatment of
1F
migraine with or without aura in adults.
The American Headache Society recommends use of NSAIDs (including aspirin), non-opioid
analgesics, acetaminophen, or caffeinated analgesic combinations (e.g.,
aspirin/acetaminophen/caffeine) for mild‐to‐moderate attacks and migraine‐specific agents
(i.e.,triptans, dihydroergotamine [DHE]) for moderate or severe attacks and mild‐to‐moderate
attacks that respond poorly to NSAIDs or caffeinated combinations.
2. Coverage Criteriaa:
A. Initial Authorization
1. Reyvow will be approved based on all of the following criteria:
a. Diagnosis of migraine headaches with or without aura.
-AND-
b. Used for acute treatment of migraine
-AND-
c. Patient is 18 years of age or older
Authorization will be issued for 12 months.
B. Reauthorization
1. Reyvow will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Programs:
• Supply limits may apply.
• Prior Authorization-Medical Necessity may apply
• Step Therapy may apply
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Reyvow [package insert]. Indianapolis, IN: Lilly USA, LLC; September 2022.
2. The American Headache Society Position Statement on Integrating New Migraine Treatments Into
Clinical Practice. AHS Consensus Statement. Headache. 2021; 61:1021-39.
Program Prior Authorization-Notification – Reyvow
Change Control
Date Change
8/2020 New program.
7/2021 Annual review. Updated references. Added state mandate language.
3/2022 Updated references.
3/2023 Annual review. Updated references.
3/2024 Annual review. No changes.
3/2025 Annual review. No changes.
© 2025 UnitedHealthcare Services, Inc.
2